CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $531 | -21.3% | 11,707 | -2.6% | 0.00% | 0.0% |
| Q2 2023 | $675 | +19.9% | 12,015 | -3.5% | 0.00% | 0.0% |
| Q1 2023 | $563 | +8.5% | 12,449 | -2.4% | 0.00% | 0.0% |
| Q4 2022 | $519 | -99.9% | 12,755 | -17.5% | 0.00% | -50.0% |
| Q3 2022 | $1,010,000 | -3.0% | 15,457 | -9.8% | 0.00% | -20.0% |
| Q2 2022 | $1,041,000 | -5.4% | 17,133 | -2.3% | 0.01% | +25.0% |
| Q1 2022 | $1,100,000 | -16.8% | 17,535 | +0.5% | 0.00% | -20.0% |
| Q4 2021 | $1,322,000 | -38.3% | 17,452 | -8.8% | 0.01% | -44.4% |
| Q3 2021 | $2,141,000 | +31.9% | 19,128 | +90.8% | 0.01% | +12.5% |
| Q2 2021 | $1,623,000 | – | 10,024 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |